Fernand Labrie

Publications

Page 3 of 4, showing 50 records out of 165 total, starting on record 101, ending on 150

Publication Category Year
4692. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. DHEA 2009
556. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Chaussade, V., Deloche, C., Leclaire, J. (2008) Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol, 110: 1-9. DHEA 2008
624. Labrie, F., Diamond, P., Cusan, L., Gomez, J.L., Bélanger, A., Candas, B. (1997) Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505. DHEA 1997
20. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. DHEA 2005
391. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. DHEA 2003
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. DHEA 2001
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. DHEA 2000
578. Labrie, F., Luu-The, V., Martel, C., Chernomoretz, A., Calvo, E., Morissette, J., Labrie, C. (2006) Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol, 100: 52-8. DHEA 2006
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. DHEA 1994
640. Labrie, Y., Couet, J., Simard, J., Labrie, F. (1994) Multihormonal regulation of dehydroepiandrosterone sulfotransferase mRNA levels in adult rat liver. Endocrinology, 134: 1693-1699. DHEA 1994
601. Leblanc, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (2002) Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J. Steroid Biochemistry & Molecular Biology, 81: 159-164. DHEA 2002
596. Leblanc, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (2003) Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J Clin Endocrinol Metab, 88 (9): 4293-302. DHEA 2003
597. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. (2003) The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes. Res., 11: 477-490. DHEA 2003
470. Li, S., Yan, X., Bélanger, A., Labrie, F. (1993) Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(?)anthracene (DMBA) in the rat. Breast Cancer Res. Treat., 29: 203-217. DHEA 1993
561. Liu, H., Bellemare, V., Labrie, F., Luu-The, V. (2007) Molecular characterization of the cynomolgus monkey Macaca fascicularis steroidogenic enzymes belonging to the aldo-keto reductase family. J Steroid Biochem Mol Biol, 104: 75-80. DHEA 2007
379. Liu, H., Zheng, S.F., Bellemare, V., Pelletier, G., Labrie, F., Luu-The, V. (2007) Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem, 8: 2 DHEA 2007
439. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. DHEA 1997
442. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. DHEA 1997
635. Luu-The, V., Dufort, I., Paquet, N., Reimnitz, G., Labrie, F. (1995) Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA Cell Biol., 14: 511-518. DHEA 1995
356. Luu-The, V., Ferraris, C., Duche, D., Bélanger, P., Leclaire, J., Labrie, F. (2007) Steroid metabolism and profile of steroidogenic gene expression in EpiskinTM: High similarity with human epidermis. J Steroid Biochem Mol Biol 107: 30-36. DHEA 2007
3560. Luu-The, V., Pelletier, G., Labrie, F. (2005) Quantitative appreciation of steroidogenic gene expression in mouse tissue: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol, 93: 269-76. DHEA 2005
432. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. DHEA 1998
608. Mauriège, P., Langin, D., Montminy, V., Martel, C., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2000) Effect of a long-term percutaneous adrenal steroid treatment on rat adipose tissue metabolism. Int. J. Obes. Relat. Metab. Disord., 24: S148-S150. DHEA 2000
598. Mauriège, P., Martel, C., Langin, D., Lacaille, M., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2003) Chronic effects of dehydroepiandrosterone on rat adipose tissue metabolism. Metabolism, 3: 264-272. DHEA 2003
4686. Mellström, D., Vandenput, L., Mallmin, H., Holmberg, AH., Lorentzon, M., Odén, A., Johansson, H., Orwoll, ES., Labrie, F., Karlsson, MK., Ljunggren, Ö., Ohlsson C. (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res, 23: 1552-1560. DHEA 2008
376. Pelletier, G., Labrie, C., Martel, C., Labrie, F. (2008) Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol, 108: 102-108. DHEA 2008
28. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17beta-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. DHEA 2004
4709. Samson, M., Labrie, F., Luu-The, V. (2009) Specific estradiol biosynthetic pathway in choriocarcinoma (JEG-3) cell line. J Steroid Biochem Mol Biol, 116: 154-159. DHEA 2009
4708. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 DHEA 2010
384. Song, D., Liu, G., Luu-The, V., Zhao, D., Wang, L., Zhang, H., Xueling, G., Li, S., Desy, L., Labrie, F., Pelletier, G. (2006) Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol, 101: 136-44. DHEA 2006
433. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. DHEA 1998
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. DHEA 2000
4683. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. DHEA 2009
4713. Stener-Victorin, E., Holm, G., Labrie, F., Nilsson, L., Janson, P.O., Ohlsson C. (2010) Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab, 95: 810-819. DHEA 2010
10. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. DHEA 2007
564. Swanson, C., Lorentzon, M., Vandenput, L., Labrie, F., Rane, A., Jakobsson, J., Chouinard, S., Bélanger, A., Ohlsson, C. (2007) Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocrinol Metab, 92: 3697-704. DHEA 2007
11. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. DHEA 2007
590. Tchernof, A., Labrie, F. (2004) Dehydroepiandrosterone, obesity and cardiovascular disease risk. A review of human studies. European Journal of Endocrinology, 151: 1-14. DHEA 2004
631. Tchernof, A., Labrie, F., Bélanger, A., Després, J.P. (1996) Obesity and metabolic complications: contribution of DHEA and other steroid hormones. J. Endocrinol, 150: S155-S164. DHEA 1996
4704. Tivesten, A., Vandenput, L., Labrie, F., Karlsson, M.K., Ljunggren, O., Mellström, D., Ohlsson, C. (2009) Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab, 94: 2482-2488. DHEA 2009
14. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. DHEA 2007
4721. Vandenput, L., Mellström, D, Karlsson, MK., Orwoll, E., Labrie, F., Ljunggren, O., Ohlsson C (2010) Serum estradiol is associated with lean mass in elderly Swedish men. European Journal of Endocrinology. 162: 737-745. DHEA 2010
567. Vandenput, L., Mellström, D., Lorentzon, M., Swanson, C., Karlsson, M.K., Brandberg, J., Lönn, L., Orwoll, E., Smith, U., Labrie, F., Ljunggren, O., Tivesten, A., Ohlsson, C. (2007) Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab, 92: 4130-7. DHEA 2007
4719. Weirman, M.E., Nappi, R.E., Avis, N., Davis, S.R., Labrie F., Rosner, W., Shifren J.L. (2010) Endocrine aspects of women's sexual function. J Sex Med. 7:561-585. DHEA 2010
580. Yoshioka, M., Boivin, A., Ye, P., Labrie, F., St-Amand, J. (2006) Effects of dihydrotestosterone on skeletal muscle transcriptome measured by serial analysis of gene expression. J Mol Endocrinol, 36: 247-259. DHEA 2006
641. Young, J., Couzinet, B., Pholsena, M., Nahoul, K., Labrie, F., Schaison, G. (1994) Plasma 3β-hydroxy-?5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 78: 299-304. DHEA 1994
199. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. DHEA 1988
280. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. DHEA 1984
1. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. DHEA 2009
205. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. DHEA 1988
<< previous | 1 | 2 | 3 | 4 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards